Insider · CIK 0001307935

Watkins Thomas

CIK 0001307935 Name as filed on the most recent filing

Filed as Watkins Thomas (17)

19 transaction lines · from 17 filings · filed 2005-01-06 to 2022-06-03 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

19 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2022-06-02 S, Open-market sale Vanda Pharmaceuticals Inc.VNDA 63,779, disposed Open Form 4 filing 0001209191-22-034062
2021-02-16 S, Open-market sale Vanda Pharmaceuticals Inc.VNDA 107,856, disposed Open Form 4 filing 0001209191-21-012205
2020-05-29 S, Open-market sale Vanda Pharmaceuticals Inc.VNDA 111,286, disposed Open Form 4 filing 0001209191-20-033491
2015-08-19 P, Open-market purchase Horizon Pharma plcHZNP 313,240, acquired Open Form 4 filing 0001209191-15-067415
2014-08-14 P, Open-market purchase Horizon Pharma plcHZNP 58,560, acquired Open Form 4 filing 0001209191-15-006347
2014-03-14 S, Open-market sale Vanda Pharmaceuticals Inc.VNDA 618,170, disposed Open Form 4 filing 0001209191-14-021015
2012-06-29 P, Open-market purchase Human Genome Sciences IncHGSI 21,260, acquired Open Form 4 filing 0001225208-12-018057
2011-06-30 P, Open-market purchase Human Genome Sciences IncHGSI 21,239, acquired Open Form 4 filing 0001225208-12-018057
2011-01-05 P, Open-market purchase Human Genome Sciences IncHGSI 1,449,600, acquired Open Form 4 filing 0001225208-11-001464
2010-07-12 P, Open-market purchase Human Genome Sciences IncHGSI 15,737, acquired Open Form 4 filing 0001225208-10-017129
2009-06-30 P, Open-market purchase Human Genome Sciences IncHGSI 1,800, acquired Open Form 4 filing 0001225208-09-014903
2008-11-12 P, Open-market purchase Human Genome Sciences IncHGSI 202,000, acquired Open Form 4 filing 0001225208-08-017887
2008-07-01 P, Open-market purchase Human Genome Sciences IncHGSI 10,242, acquired Open Form 4 filing 0001225208-08-011367
2008-03-11 P, Open-market purchase Human Genome Sciences IncHGSI 2 lines 98,700, acquired Open Form 4 filing 0001225208-08-004816
2007-07-11 P, Open-market purchase Human Genome Sciences IncHGSI 15,126, acquired Open Form 4 filing 0000901219-07-000071
2006-11-10 P, Open-market purchase Human Genome Sciences IncHGSI 72,300, acquired Open Form 4 filing 0000901219-06-000068
2006-09-05 P, Open-market purchase Human Genome Sciences IncHGSI 334,200, acquired Open Form 4 filing 0000901219-06-000044
2005-01-05 P, Open-market purchase Human Genome Sciences IncHGSI 119,500, acquired Open Form 4 filing 0000901219-05-000004

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 15
  • Open-market sale 4
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Watkins Thomas, insider transactions. Retrieved 2026-08-22 from https://ebomi.com/insider/0001307935

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.